Clinical Trials Browser

Has announcements × Myeloproliferative Disorders × Clear all

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

47 enrolled 21 charts 1 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT01844765 2021-04-22

DIALOG

Phase 2 Completed

59 enrolled 33 charts 1 FDA

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive